Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2012 Dec 14;30(52):7443-6. doi: 10.1016/j.vaccine.2012.10.025. Epub 2012 Oct 19.

The economic value of a quadrivalent versus trivalent influenza vaccine.

Author information

1
Public Health Computational and Operations Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States. BYL1@pitt.edu

Erratum in

  • Vaccine. 2013 May 7;31(20):2477-9.

Abstract

The recently licensed quadrivalent seasonal influenza vaccine (QIV) may provide better protection than the traditional trivalent influenza vaccine (TIV) as it includes one more influenza B strain. We developed a Monte Carlo simulation model to determine the economic value of a QIV compared to the TIV for 10 influenza seasons (1999-2009). The addition of the influenza B strain to convert the TIV into a QIV could result in substantial cost-savings to society (median of $3.1 billion) and third party payers (median of $292 million), even when the cost of QIV is significantly higher.

PMID:
23084849
PMCID:
PMC3696129
DOI:
10.1016/j.vaccine.2012.10.025
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center